scholarly journals Impaired fasting pyloric compliance in gastroparesis and the therapeutic response to pyloric dilatation

2014 ◽  
Vol 41 (4) ◽  
pp. 360-367 ◽  
Author(s):  
G. Gourcerol ◽  
F. Tissier ◽  
C. Melchior ◽  
J. Y. Touchais ◽  
E. Huet ◽  
...  
Keyword(s):  
Therapeutic Response ◽  
Pyloric Dilatation

Relation between dosage, serum concentration and therapeutic response of risperidone in children and adolescents with schizophrenic psychosis: data from a routine TDM-Service

2014 ◽  
Vol 47 (06) ◽  
Author(s):  
K Egberts ◽  
A Preuss ◽  
C Wewetzer ◽  
S Unterecker ◽  
P Plener ◽  
...  
Keyword(s):  
Serum Concentration ◽  
Children And Adolescents ◽  
Therapeutic Response ◽  
Schizophrenic Psychosis

Does a therapeutic response to rTMS predict successful VNS therapy?

2008 ◽  
Vol 39 (01) ◽  
Author(s):  
B Steinhoff ◽  
AS Wendling
Keyword(s):  
Therapeutic Response

Ixekizumab in the Management of Non-Selected Out Patients with Moderate to Severe Psoriasis -New Data and Personal Clinical Experience

2018 ◽  
Vol 3 (3) ◽  
Keyword(s):  
Clinical Experience ◽  
Personal Experience ◽  
Therapeutic Response ◽  
Systemic Disease ◽  
Severe Psoriasis ◽  
Adequate Treatment ◽  
Scalp Psoriasis ◽  
Number Of Patients ◽  
Genital Psoriasis

Introduction: Too many patients with moderate to severe psoriasis do not receive adequate treatment. This means a vast undersupply in the treatment of patients with psoriasis. Only biologics fulfill the whole range of the treatment of psoriasis – psoriasis does not affect only skin but the whole organism: It is a systemic disease! Between the biologics are evident differences concerning the effect. Discussion: Based on broad personal experience in the management of patients with moderate to severe psoriasis new data from clinical studies with ixekizumab are examined. This contains new data on long-term-efficacy of ixekizumab, effectiveness in special localizations (scalp psoriasis, nail psoriasis, palmoplantar psoriasis, genital psoriasis) as well as safely data and experience on patients switched to ixekizumab from other biologics. Personal clinical experience is based on >300 non-selected outpatients with moderate to severe psoriasis, >250 patients on biological therapies, > 50 patients with ixekizumab. Conclusions: Focusing on a relevant number of patients switched from secukinumab to ixekizumab due to first or secondary loss of efficacy significant differences between both IL-17A-inhibitors mainly in terms of efficacy and speed of therapeutic response are shown. Finally the correlation between PASI-90-/PASI-100 response and significant changes in DLQI are highlighted.

Assessment of therapeutic response in osteoporosis

2013 ◽  
Author(s):  
Adolfo Diez-Perez
Keyword(s):  
Therapeutic Response

Therapeutic response to recombinat somatropin in children with isolated deficiency of GH

2013 ◽  
Author(s):  
Sandra Belo ◽  
Claudia Nogueira ◽  
Susana Corujeira ◽  
Carla Costa ◽  
Cintia Castro-Correia ◽  
...  
Keyword(s):  
Therapeutic Response

Thyroid dysfunction during the use of PD-1/PD-L1 blockade predicts its therapeutic response in the patients with advanced non-small cell lung cancer

2017 ◽  
Author(s):  
Hye In Kim ◽  
Tae Hyuk Kim ◽  
Hye Won Jang ◽  
Young Nam Kim ◽  
Hosu Kim ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Thyroid Dysfunction ◽  
Therapeutic Response ◽  
Small Cell ◽  
Small Cell Lung

Clinical predictors of therapeutic response to SGLT-2 inhibitors

2018 ◽  
Author(s):  
Carolina Garcia-Figueras-Mateos ◽  
Manuel Cayon-Blanco
Keyword(s):  
Therapeutic Response ◽  
Clinical Predictors

Imaging cardiac sarcoidosis and infiltrative diseases: diagnosis and therapeutic response

2020 ◽  
Vol 64 (1) ◽  
Author(s):  
Mohamed Y. Elwazir ◽  
John P. Bois ◽  
Omar F. Abouezzeddine ◽  
Panithaya Chareonthaitawee
Keyword(s):  
Therapeutic Response ◽  
Cardiac Sarcoidosis
Sign in / Sign up

Export Citation Format

Share Document